US Edition
High-Fidelity Cas9-Mediated Targeting of KRAS Driver Mutations Restrains Lung Cancer in Preclinical Models
Summary by Stemwell Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
High-Fidelity Cas9-Mediated Targeting of KRAS Driver Mutations Restrains Lung Cancer in Preclinical Models
Investigators developed a CRISPR-High Fidelity-Cas9-based therapy strategy that can effectively and specifically target KRASG12C and KRASG12D mutants, avoiding KRASWT off-targeting and affecting KRAS downstream pathways, thereby significantly reducing tumorgenicity. [Nature Communications] Full Article
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
